Trial · NCT01589302
Adverse events158
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
61 to 80 of 158
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hyperglycemia | Metabolism and nutrition disorders | Treatment (Ibrutinib) | 17 | 152 | 30 |
| other | Hyperkalemia | Metabolism and nutrition disorders | Treatment (Ibrutinib) | 8 | 152 | 9 |
| other | Hyperuricemia | Metabolism and nutrition disorders | Treatment (Ibrutinib) | 17 | 152 | 25 |
| other | Hypokalemia | Metabolism and nutrition disorders | Treatment (Ibrutinib) | 9 | 152 | 14 |
| other | Hyponatremia | Metabolism and nutrition disorders | Treatment (Ibrutinib) | 14 | 152 | 15 |
| other | Hypophosphatemia | Metabolism and nutrition disorders | Treatment (Ibrutinib) | 12 | 152 | 15 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Treatment (Ibrutinib) | 56 | 152 | 77 |
| other | Arthritis | Musculoskeletal and connective tissue disorders | Treatment (Ibrutinib) | 24 | 152 | 26 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Treatment (Ibrutinib) | 37 | 152 | 41 |
| other | Bone pain | Musculoskeletal and connective tissue disorders | Treatment (Ibrutinib) | 12 | 152 | 12 |
| other | Musculoskeletal and Connective tissue disorder-other | Musculoskeletal and connective tissue disorders | Treatment (Ibrutinib) | 104 | 152 | 123 |
| other | Myalgia | Musculoskeletal and connective tissue disorders | Treatment (Ibrutinib) | 29 | 152 | 34 |
| other | Neck pain | Musculoskeletal and connective tissue disorders | Treatment (Ibrutinib) | 9 | 152 | 10 |
| other | Pain Extremity | Musculoskeletal and connective tissue disorders | Treatment (Ibrutinib) | 29 | 152 | 34 |
| other | Neoplasms benign, malignant and unspecified-other | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Treatment (Ibrutinib) | 37 | 152 | 49 |
| other | Dizziness | Nervous system disorders | Treatment (Ibrutinib) | 55 | 152 | 69 |
| other | Dysgeusia | Nervous system disorders | Treatment (Ibrutinib) | 17 | 152 | 18 |
| other | Headache | Nervous system disorders | Treatment (Ibrutinib) | 63 | 152 | 79 |
| other | Nervous System Disorders-other | Nervous system disorders | Treatment (Ibrutinib) | 10 | 152 | 10 |
| other | Paresthesia | Nervous system disorders | Treatment (Ibrutinib) | 48 | 152 | 54 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01589302/events?page=4